QL2109

daratumumab biosimilar · Qilu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for QL2109, covering 2024-12-19 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects [Phase 1]